Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Immpact Bio USA Inc.
Headquarters: West Hills, CA, United States of America
Website: N/A
Year Founded: 2017
Status: Acquired
BioCentury | Apr 2, 2025
Management Tracks
Change at the top for Phathom as Basta replaces Curran
Plus: Updates from Nuage, GV, Inhibrx, Lyell, Repare, Adcendo, ITM Isotope, Transgene and Novartis
BioCentury | Nov 21, 2024
Product Development
Companies get creative with multi-targeted CARs at SITC, ASH
BioCentury’s analysis of the SITC, ASH abstracts highlights progress in bicistronic and tandem CAR Ts
BioCentury | Oct 31, 2023
Management Tracks
CSO, CFO changes at Third Harmonic
Plus: MediLink hires Steve Chin as CMO, and updates from ImmPACT,
BioCentury | Oct 5, 2023
Product Development
Innovation in autoimmune CAR Ts doesn’t stop at CD19
Dual targeting, allogeneic designs and novel targets are all under investigation to help CAR T cells reach more autoimmune patients
BioCentury | Aug 4, 2023
Management Tracks
Karuna names new CFO and HR head
Plus: Freeman joins Zentalis as chief strategy officer, and updates from Complement,
BioCentury | Mar 24, 2023
Product Development
Landscape of emerging T cell therapies in cancer
Four axes of risk map how companies founded in the last five years are innovating in CAR T and TCR T cells
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Sep 13, 2022
Management Tracks
New CMOs at ImmPACT, Smart Immune
Plus CEO named at Prolifagen, and updates from Endpoint, Veracyte, Vyriad and more
BioCentury | Aug 10, 2022
Management Tracks
New CMOs at Arcus, Enanta
Plus Lamba becomes CFO at ImmPACT, and updates from Appia Bio and Quanterix
BioCentury | May 11, 2022
Management Tracks
Shea replacing Kim as CEO of Inovio
Plus new chief commercial officer at DNA Script, and updates from Boston Pharma, Quantum SI, Beta, Longeveron and more
Items per page:
1 - 10 of 15